Alentis Therapeutics Lands $105M for Clinical Trials in Fibrosis and Cancer
Three months after Alentis Therapeutics’ lead program posted positive Phase 1 data, the biotech has raised cash to advance that program to mid-stage testing in fibrosis. The Series C financing will also support a cancer drug candidate ready to start human testing.